Vesalius Biocapital has led a €50m series-B funding round for cancer immunotherapy developer CatalYm.
Tom Alzin and Jannick Hunnecke will join, while Rolf Scheffels is to leave when his term ends
Fund focuses on investment opportunities in the lower-mid-market across North America and Europe
Frank Bretag joins from Georgieff Capital Advisors and focuses on the industrial goods sector
Enterprise Investors acquired a minority stake in the oncology company in 2013